Navigation Links
Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
Date:3/26/2008

MOUNTAIN VIEW, Calif., March 26 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development announced today that it will be presenting at B. Riley & Co. 9th Annual Las Vegas Investor Conference on April 2, 2008 at the Palms Las Vegas. Shawn O'Connor, Pharsight's President and CEO, and William Frederick, Senior Vice President and CFO, will be presenting on April 2nd, at 1:30 p.m. PT.

Attendance at the conference is by invitation only. A live audio webcast of the presentation with slides will be broadcast via the Internet. The webcast can be viewed at the company's website under the investor relations section at http://www.pharsight.com.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.c
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
2. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
3. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
4. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
5. Pharsight Achieves $7.4 Million in Quarterly Revenue
6. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
7. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. Pharsight Announces 1-For-3 Reverse Stock Split
10. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
11. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Rainbow Scientific, Inc. (RSI), ... the availability of BI’s line of human mesenchymal stem cell (hMSC) differentiation media, ... media offer a complete system for multipotency evaluation of hMSCs and reliable induction ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... Market Research, a global provider of pharmaceutical competitive intelligence ... "Thought Leader Insight & Analysis: Alzheimer,s Disease," designed to ... with a stake in the market for diagnostics and ... ). , , MedPredict interviewed ...
... ... On-Site at Komen Western New York Race for the Cure® , ... Ottawa, ON (PRWEB) June 12, 2009 -- DNA Genotek , a ... Roswell Park Cancer Institute (RPCI) to collect DNA saliva samples on-site at the Susan ...
... ... biofuels could be entering the tanks of aircraft, according to the Geneva-based Air Transport Action ... this "new age in flight", the group this week launches a new publication, The Beginner,s ... ...
Cached Biology Technology:New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 3Welcome to the Biofuel Age of Flight 2Welcome to the Biofuel Age of Flight 3
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... -- Today, oxygen takes up a hefty portion of Earth,s ... air we breathe. However, very early in Earth,s history, O2 ... in the turbulent mix of primordial gases. It wasn,t until ... when oxygen made any measurable dent in the atmosphere, stimulating ...
... salt for all seasons. It turns up not only in ... coral reefs and even in pearls. The compound exists ... it is not clear what determines which variant an organism ... A team of researchers led by LMU geobiologist Dr. Azizur ...
... at risk for a certain form of colon and other ... surviving or even avoiding the diseases, thanks to a new ... Hospital. The Intermountain Heathcare group of scientists used sophisticated ... identify patients who may have Lynch syndrome, an inherited cancer ...
Cached Biology News:MIT: Oxygen's watery past 2MIT: Oxygen's watery past 3New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3
... General description: Aminopropylsilane ... commonly used slide chemistry ... APS Coated Slides for ... reliable glass substrate for ...
Designed for use with any of the Agencourt kits in tube format....
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,405-4) or contact customer service ... mm volume diam. 3 mL ...
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
Biology Products: